Apatinib plus Chemotherapy as a Second‐Line Treatment in Unresectable Non‐Small Cell Lung Carcinoma: A Randomized, Controlled, Multicenter Clinical Trial

LESSONS LEARNED: The efficacy of second‐line treatment for advanced non‐small cell lung carcinoma (NSCLC) without a sensitizing driver gene mutation is still unsatisfactory. The combination of apatinib and chemotherapy improved progression‐free survival in the second‐line therapy of advanced NSCLC w...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Oncologist
Main Authors: Yu, Zongyang, Cai, Xiuyu, Xu, Zhengwu, He, Zhiyong, Lai, Jinhuo, Wang, Wenwu, Zhang, Jing, Kong, Wencui, Huang, Xiaoyan, Chen, Ying, Shi, Yanhong, Shi, Xi, Zhao, Zhongquan, Ni, Min, Lin, Xiangwu, Chen, Siyu, Wu, Xiaolong, Chen, Wujin, Song, Zhengbo, Huang, Cheng
פורמט: Artigo
שפה:Inglês
יצא לאור: John Wiley & Sons, Inc. 2020
נושאים:
Clinical Trial Results
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7648327/
https://ncbi.nlm.nih.gov/pubmed/32533785
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0519
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים